Literature DB >> 15678271

Comparative tissue factor pathway inhibitor release potential of heparins.

M Tobu1, Q Ma, O Iqbal, C Schultz, W Jeske, D A Hoppensteadt, J Fareed.   

Abstract

Tissue factor pathway inhibitor (TFPI) is released following the administration of unfractionated heparin, low-molecular-weight heparins, defibrotide and PI-88. In this study, the comparative effects of heparin, a low-molecular-weight heparin-gammaparin and a heparin-derived oligosaccharide mixture-subeparin (C3) were studied on functional and immunologic tissue factor pathway inhibitor activity levels in a non-human primate (Macaca mulatta) model. The dose-dependent effect was studied following intravenous and subcutaneous administration. Following the administration of 1 mg/kg of heparin, gammaparin, and C3, the functional levels of TFPI at 5 minutes were 2.40, 2.56, and 1.08 U/mL and the corresponding TFPI immunologic levels were 4.3-, 4.0-, and 2.1-fold, increased, respectively, over the baseline value. From these results, it can be concluded that heparin and gammaparin produced similar levels of TFPI release. Hence, gammaparin and heparin have similar TFPI release potential despite their differences in molecular weight. The influence of molecular weight, charge density, and interactions with heparin cofactor II on TFPI release are also discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15678271     DOI: 10.1177/107602960501100104

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  3 in total

1.  The effects of continuous venovenous hemofiltration on coagulation activation.

Authors:  Catherine S C Bouman; Anne-Cornélie J M de Pont; Joost C M Meijers; Kamran Bakhtiari; Dorina Roem; Sacha Zeerleder; Gertjan Wolbink; Johanna C Korevaar; Marcel Levi; Evert de Jonge
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

2.  Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model.

Authors:  Ernesto Luna; Pankaj Agrawal; Riyaz Mehta; Charlotte Vernhes; Christian Viskov; Jean Amiral; William L Warren; Donald R Drake
Journal:  Clin Appl Thromb Hemost       Date:  2014-12-18       Impact factor: 2.389

3.  Defibrotide enhances fibrinolysis in human endotoxemia - a randomized, double blind, crossover trial in healthy volunteers.

Authors:  Christian Schoergenhofer; Nina Buchtele; Georg Gelbenegger; Ulla Derhaschnig; Christa Firbas; Katarina D Kovacevic; Michael Schwameis; Philipp Wohlfarth; Werner Rabitsch; Bernd Jilma
Journal:  Sci Rep       Date:  2019-07-31       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.